Home/Filings/4/0001415889-25-012289
4//SEC Filing

Rochlin Kate 4

Accession 0001415889-25-012289

CIK 0001740279other

Filed

May 6, 8:00 PM ET

Accepted

May 7, 8:45 PM ET

Size

16.9 KB

Accession

0001415889-25-012289

Insider Transaction Report

Form 4
Period: 2025-04-27
Rochlin Kate
Chief Operating Officer
Transactions
  • Disposition to Issuer

    Series A Warrants (right to buy)

    2025-04-2712,2950 total
    Exercise: $0.45Exp: 2025-10-04Common Stock (12,295 underlying)
  • Exercise/Conversion

    Series A Warrants (right to buy)

    2025-04-3012,2950 total
    Exercise: $0.18Exp: 2025-05-02Common Stock (12,295 underlying)
  • Exercise/Conversion

    Common Stock

    2025-04-30$0.18/sh+12,295$2,26755,169 total
  • Award

    Series A Warrants (right to buy)

    2025-04-27+12,29512,295 total
    Exercise: $0.18Exp: 2025-05-02Common Stock (12,295 underlying)
  • Disposition to Issuer

    Series B Warrants (right to buy)

    2025-04-2712,2950 total
    Exercise: $1.50Exp: 2028-12-13Common Stock (12,295 underlying)
  • Award

    Series B Warrants (right to buy)

    2025-04-27+12,29512,295 total
    Exercise: $0.45Exp: 2028-12-13Common Stock (12,295 underlying)
Footnotes (4)
  • [F1]The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025.
  • [F2]Fully vested and exercisable.
  • [F3]The reported securities are included within 12,295 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 12,295 shares of common stock.
  • [F4]The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.

Issuer

IN8BIO, INC.

CIK 0001740279

Entity typeother

Related Parties

1
  • filerCIK 0001898521

Filing Metadata

Form type
4
Filed
May 6, 8:00 PM ET
Accepted
May 7, 8:45 PM ET
Size
16.9 KB